Skip to main content
SpringerLink
Log in

Anhedonia in Parkinson’s Disease and Other Movement Disorders

  • Chapter
  • First Online:
Anhedonia: A Comprehensive Handbook Volume II

  • 1362 Accesses

Abstract

Anhedonia, defined as lowered ability to experience physical or social pleasure, is a frequent symptom in patients with Parkinson’s disease (PD). In this population, most studies report an association of anhedonia with neuropsychiatric disorders and syndromes such as depression, apathy and cognitive decline. Reports on the relationship between anhedonia and severity of motor symptoms in PD are inconclusive. The presence of anhedonia is diagnosed on the basis of history and mental status examination; its severity can be assessed by available rating scales. Several studies described anhedonia as strictly associated to depression in PD and probably related to degeneration of mesolimbic and mesocortical dopamine projections, thus contributing directly to the high incidence of depression and consequently of anhedonia in PD patients. This is supported by the observation that inhibition of dopamine system via D2 receptor antagonists can be accompanied by reduced motivation, drive and spontaneity, and dysphoria.

In contrast to PD, data on anhedonia in other movement disorders are still scarce.

Future research should be directed to a better understanding of the etiology and pathophysiology of anhedonia in order to be able to identify and provide new strategies for treatment of this neuropsychiatric phenomenon.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

DBS-STN:

Deep brain stimulation of the subthalamic nucleus

DSM:

Diagnostic and Statistical Manual of Mental Disorders

DSM-IV-TR:

The fourth revised edition of the DSM

ICD-10:

International Classification of Diseases

PD:

Parkinson’s disease

References

  1. de Rijk MC, Rocca WA, Anderson DW, et al. A population perspective on diagnostic criteria for Parkinson’s disease. Neurology. 1997;48(5):1277–81.

    PubMed  Google Scholar 

  2. Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641–9.

    PubMed  Google Scholar 

  3. Leentjens AFG. Epidemiology of psychiatric symptoms in Parkinson’s disease. Adv Biol Psychiatry. 2012;27:1–12.

    Google Scholar 

  4. Wolters EC. Dopaminomimetic psychosis in Parkinson’s disease patients: diagnosis and treatment. Neurology. 1999;52(7 Suppl 3):S10–3.

    CAS  PubMed  Google Scholar 

  5. Leentjens AF, Van den Akker M, Metsemakers JF, et al. Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord. 2003;18(4):414–8.

    PubMed  Google Scholar 

  6. Schuurman AG, van den Akker M, Ensinck KT, et al. Increased risk of Parkinson’s disease after depression: a retrospective cohort study. Neurology. 2002;58(10):1501–4.

    CAS  PubMed  Google Scholar 

  7. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson’s disease: a case–control study. Mov Disord. 2000;15(4):669–77.

    CAS  PubMed  Google Scholar 

  8. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211.

    PubMed  Google Scholar 

  9. Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3(3):243–54.

    CAS  PubMed  Google Scholar 

  10. Kitanaka J, Kitanaka N, Takemura M. Neurochemical consequences of dysphoric state during amphetamine withdrawal in animal models: a review. Neurochem Res. 2008;33(1):204–19.

    CAS  PubMed  Google Scholar 

  11. Stevens A, Peschk I, Schwarz J. Implicit learning, executive function and hedonic activity in chronic polydrug abusers, currently abstinent polydrug abusers and controls. Addiction. 2007;102(6):937–46.

    PubMed  Google Scholar 

  12. Vacca G, Ahn S, Phillips AG. Effects of short-term abstinence from escalating doses of D-amphetamine on drug and sucrose-evoked dopamine efflux in the rat nucleus accumbens. Neuropsychopharmacology. 2007;32(4):932–9.

    CAS  PubMed  Google Scholar 

  13. Cohen AS, Leung WW, Saperstein AM, et al. Neuropsychological functioning and social anhedonia: results from a community high-risk study. Schizophr Res. 2006;85(1–3):132–41.

    PubMed  Google Scholar 

  14. Gard DE, Kring AM, Gard MG, et al. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res. 2007;93(1–3):253–60.

    PubMed Central  PubMed  Google Scholar 

  15. Winograd-Gurvich C, Fitzgerald PB, Georgiou-Karistianis N, et al. Negative symptoms: a review of schizophrenia, melancholic depression and Parkinson’s disease. Brain Res Bull. 2006;70(4–6):312–21.

    CAS  PubMed  Google Scholar 

  16. Harvey PO, Pruessner J, Czechowska Y, et al. Individual differences in trait anhedonia: a structural and functional magnetic resonance imaging study in non-clinical subjects. Mol Psychiatry. 2007;12(8):703, 767–75.

    Google Scholar 

  17. Di Giuda D, Camardese G, Bentivoglio AR, et al. Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging. 2012;39(12):1937–48.

    CAS  PubMed  Google Scholar 

  18. Kim WH, Lee YS, Jung SH, et al. Major depressive disorder preceding the onset of progressive supranuclear palsy. Psychiatry Invest. 2009;6(2):112–4.

    Google Scholar 

  19. Miller KM, Okun MS, Fernandez HF, et al. Depression symptoms in movement disorders: comparing Parkinson’s disease, dystonia, and essential tremor. Mov Disord. 2007;22(5):666–72.

    PubMed  Google Scholar 

  20. Paulsen JS, Nehl C, Hoth KF, et al. Depression and stages of Huntington’s disease. J Neuropsychiatry Clin Neurosci. 2005;17(4):496–502.

    PubMed  Google Scholar 

  21. Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. Mov Disord. 2010;25(8):1077–81.

    PubMed  Google Scholar 

  22. Vaccarino AL, Sills T, Anderson KE, et al. Assessment of depression, anxiety and apathy in prodromal and early Huntington disease. PLoS Curr. 2011;3:RRN1242.

    PubMed Central  PubMed  Google Scholar 

  23. Ribot TH. The psychology of emotions. London: W Scott Pub. Co.; New York: C. Scribner’s; 1903.

    Google Scholar 

  24. APA. Diagnostic and statistical manual of mental disorders. 3rd ed. (DSM-III) Washington, DC: APA; 1980.

    Google Scholar 

  25. WHO. The ICD–10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: WHO; 1992.

    Google Scholar 

  26. APA. Diagnostic and statistical manual of mental disorders 4th text revised (DSM-IV-TR). Washington, DC: APA; 2000.

    Google Scholar 

  27. Sims A. Symptoms in the mind. London: Balliere Tindall; 1988.

    Google Scholar 

  28. Loas G, Krystkowiak P, Godefroy O. Anhedonia in Parkinson’s disease: an overview. J Neuropsychiatry Clin Neurosci. 2012;24(4):444–51.

    PubMed  Google Scholar 

  29. Leentjens AFG, Dujardin K, Marsh L, et al. Apathy and anhedonia rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2008;23(14):2004–14.

    PubMed  Google Scholar 

  30. Assogna F, Cravello L, Caltagirone C, et al. Anhedonia in Parkinson’s disease: a systematic review of the literature. Mov Disord. 2011;26(10):1825–34.

    PubMed  Google Scholar 

  31. Weintraub D, Cary MS, Stern MB, et al. Daily affect in Parkinson disease is responsive to life events and motor symptoms. Am J Geriatr Psychiatry. 2006;14(2):161–8.

    PubMed  Google Scholar 

  32. Robert P, Onyike CU, Leentjens AF, et al. Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. Eur Psychiatry. 2009;24(2):98–104.

    CAS  PubMed  Google Scholar 

  33. APA. Diagnostic and statistical manual of mental disorder. 4th ed. (DSM-IV) Washington, DC: APA; 1994.

    Google Scholar 

  34. Snaith RP, Hamilton M, Morley S, et al. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995;167(1):99–103.

    CAS  PubMed  Google Scholar 

  35. Chapman LJ, Chapman JP, Raulin ML. Scales for physical and social anhedonia. J Abnorm Psychol. 1976;85(4):374–82.

    CAS  PubMed  Google Scholar 

  36. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson’s disease: critique and recommendations. Mov Disord. 2007;22(8):1077–92.

    PubMed Central  PubMed  Google Scholar 

  37. Isella V, Iurlaro S, Piolti R, et al. Physical anhedonia in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2003;74(9):1308–11.

    CAS  PubMed  Google Scholar 

  38. Lemke MR, Brecht HM, Koester J, et al. Anhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci. 2005;17(2):214–20.

    CAS  PubMed  Google Scholar 

  39. Reichmann H, Brecht MH, Koster J, et al. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson’s disease. CNS Drugs. 2003;17(13):965–73.

    CAS  PubMed  Google Scholar 

  40. Dujardin K, Sockeel P, Devos D, et al. Characteristics of apathy in Parkinson’s disease. Mov Disord. 2007;22(6):778–84.

    PubMed  Google Scholar 

  41. Pluck GC, Brown RG. Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73(6):636–42.

    CAS  PubMed  Google Scholar 

  42. Starkstein SE, Merello M, Jorge R, et al. The syndromal validity and nosological position of apathy in Parkinson’s disease. Mov Disord. 2009;24(8):1211–6.

    PubMed  Google Scholar 

  43. Drijgers RL, Dujardin K, Reijnders JS, et al. Validation of diagnostic criteria for apathy in Parkinson’s disease. Parkinsonism Relat Disord. 2010;16(10):656–60.

    PubMed  Google Scholar 

  44. Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord. 2008;23(2):183–9; quiz 313.

    PubMed  Google Scholar 

  45. Fibiger HC. The neurobiological substrates of depression in Parkinson’s disease: a hypothesis. Can J Neurol Sci. 1984;11(1 Suppl):105–7.

    CAS  PubMed  Google Scholar 

  46. Cantello R, Aguggia M, Gilli M, et al. Major depression in Parkinson’s disease and the mood response to intravenous methylphenidate: possible role of the “hedonic” dopamine synapse. J Neurol Neurosurg Psychiatry. 1989;52(6):724–31.

    CAS  PubMed  Google Scholar 

  47. Fleminger S. Left-sided Parkinson’s disease is associated with greater anxiety and depression. Psychol Med. 1991;21(3):629–38.

    CAS  PubMed  Google Scholar 

  48. Rockwell E, Choure J, Galasko D, et al. Psychopathology at initial diagnosis in dementia with Lewy bodies versus Alzheimer disease: comparison of matched groups with autopsy-confirmed diagnoses. Int J Geriatr Psychiatry. 2000;15(9):819–23.

    CAS  PubMed  Google Scholar 

  49. Lemke MR, Brecht HM, Koester J, et al. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson’s disease. J Neurol Sci. 2006;248(1–2):266–70.

    CAS  PubMed  Google Scholar 

  50. Lieberman A. Are dementia and depression in Parkinson’s disease related? J Neurol Sci. 2006;248:138–42.

    PubMed  Google Scholar 

  51. Ehrt U, Bronnick K, Leentjens AF, et al. Depressive symptom profile in Parkinson’s disease: a comparison with depression in elderly patients without Parkinson’s disease. Int J Geriatr Psychiatry. 2006;21(3):252–8.

    PubMed  Google Scholar 

  52. Zheng J, Sun S, Qiao X, et al. Depression in patients with Parkinson’s disease and the associated features. J Huazhong Univ Sci Technolog Med Sci. 2009;29(6):725–8.

    PubMed  Google Scholar 

  53. Santangelo G, Vitale C, Trojano L, et al. Relationship between depression and cognitive dysfunctions in Parkinson’s disease without dementia. J Neurol. 2009;256(4):632–8.

    CAS  PubMed  Google Scholar 

  54. Santangelo G, Morgante L, Savica R, et al. Anhedonia and cognitive impairment in Parkinson’s disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. Parkinsonism Relat Disord. 2009;15(8):576–81.

    CAS  PubMed  Google Scholar 

  55. Pouladi MA, Graham RK, Karasinska JM, et al. Prevention of depressive behaviour in the YAC 128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain. 2009;132:919–32.

    PubMed  Google Scholar 

  56. Kaji Y, Hirata K. Apathy and anhedonia in Parkinson’s disease. ISRN Neurol. 2011;2011:219427.

    PubMed Central  PubMed  Google Scholar 

  57. Fujiwara S, Kimura F, Hosokawa T, et al. Anhedonia in Japanese patients with Parkinson’s disease. Geriatr Gerontol Int. 2011;11(3):275–81.

    PubMed  Google Scholar 

  58. Miura S, Kida H, Nakajima J, et al. Anhedonia in Japanese patients with Parkinson’s disease: analysis using the Snaith-Hamilton Pleasure Scale. Clin Neurol Neurosurg. 2012;114(4):352–5.

    PubMed  Google Scholar 

  59. Zahodne LB, Marsiske M, Okun MS, et al. Components of depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2012;25(3):131–7.

    PubMed Central  PubMed  Google Scholar 

  60. Zahodne LB, Marsiske M, Bowers D. A latent class analysis of psychological disturbance in Parkinson’s disease. Int J Geriatr Psychiatry. 2013;28:1054–60. doi:10.1002/gps.3927.

    PubMed  Google Scholar 

  61. Spalletta G, Fagioli S, Meco G, et al. Hedonic tone and its mood and cognitive correlates in Parkinson’s disease. Depress Anxiety. 2013;30(1):85–91.

    PubMed  Google Scholar 

  62. Snaith RP. Identifying depression: the significance of anhedonia. Hosp Pract (Off Ed). 1993;28(9A):55–60.

    CAS  Google Scholar 

  63. Taylor AE, Saint-Cyr JA. Depression in Parkinson’s disease: reconciling physiological and psychological perspectives. J Neuropsychiatry Clin Neurosci. 1990;2(1):92–8.

    CAS  PubMed  Google Scholar 

  64. Poewe W. Non-motor symptoms in Parkinson’s disease. Eur J Neurol. 2008;15 Suppl 1:14–20.

    PubMed  Google Scholar 

  65. Witt K, Daniels C, Herzog J, et al. Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2006;18(3):397–401.

    CAS  PubMed  Google Scholar 

  66. Bermanzohn PC, Siris SG. Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms of schizophrenia. Compr Psychiatry. 1992;33(4):221–32.

    CAS  PubMed  Google Scholar 

  67. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427–42.

    CAS  PubMed  Google Scholar 

  68. Aarsland D, Bronnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2009;80(8):928–30.

    CAS  PubMed  Google Scholar 

  69. Oguru M, Tachibana H, Toda K, et al. Apathy and depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2010;23(1):35–41.

    PubMed  Google Scholar 

  70. Troster AI, Stalp LD, Paolo AM, et al. Neuropsychological impairment in Parkinson’s disease with and without depression. Arch Neurol. 1995;52(12):1164–9.

    CAS  PubMed  Google Scholar 

  71. Pedersen KF, Alves G, Aarsland D, et al. Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study. J Neurol Neurosurg Psychiatry. 2009;80(11):1279–82.

    CAS  PubMed  Google Scholar 

  72. Holroyd S, Currie LJ, Wooten GF. Depression is associated with impairment of ADL, not motor function in Parkinson disease. Neurology. 2005;64(12):2134–5.

    PubMed  Google Scholar 

  73. Liu CY, Wang SJ, Fuh JL, et al. The correlation of depression with functional activity in Parkinson’s disease. J Neurol. 1997;244(8):493–8.

    CAS  PubMed  Google Scholar 

  74. Global Parkinson’s Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord. 2002;17(1):60–7.

    Google Scholar 

  75. Hobson P, Holden A, Meara J. Measuring the impact of Parkinson’s disease with the Parkinson’s Disease Quality of Life questionnaire. Age Ageing. 1999;28(4):341–6.

    CAS  PubMed  Google Scholar 

  76. Ravina B, Camicioli R, Como PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007;69(4):342–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  77. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308–12.

    CAS  PubMed  Google Scholar 

  78. Royall DR, Mahurin RK, Gray KF. Bedside assessment of executive cognitive impairment: the executive interview. J Am Geriatr Soc. 1992;40(12):1221–6.

    CAS  PubMed  Google Scholar 

  79. Heinz A, Schmidt LG, Reischies FM. Anhedonia in schizophrenic, depressed, or alcohol-dependent patients–neurobiological correlates. Pharmacopsychiatry. 1994;27 Suppl 1:7–10.

    PubMed  Google Scholar 

  80. Uhl GR, Hedreen JC, Price DL. Parkinson’s disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology. 1985;35(8):1215–8.

    CAS  PubMed  Google Scholar 

  81. Javoy-Agid F, Agid Y. Is the mesocortical dopaminergic system involved in Parkinson disease? Neurology. 1980;30(12):1326–30.

    CAS  PubMed  Google Scholar 

  82. Kunig G, Leenders KL, Martin-Solch C, et al. Reduced reward processing in the brains of Parkinsonian patients. Neuroreport. 2000;11(17):3681–7.

    CAS  PubMed  Google Scholar 

  83. Braak H, Braak E. Pathoanatomy of Parkinson’s disease. J Neurol. 2000;247 Suppl 2:II3–10.

    PubMed  Google Scholar 

  84. Bench CJ, Friston KJ, Brown RG, et al. Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions. Psychol Med. 1993;23(3):579–90.

    CAS  PubMed  Google Scholar 

  85. Bressan RA, Crippa JA. The role of dopamine in reward and pleasure behaviour–review of data from preclinical research. Acta Psychiatr Scand. 2005;111 Suppl 427:14–21. doi:10.1111/j.1600-0447.2005.00540.x.

    Google Scholar 

  86. Grafton ST. Contributions of functional imaging to understanding parkinsonian symptoms. Curr Opin Neurobiol. 2004;14(6):715–9.

    CAS  PubMed  Google Scholar 

  87. Heinz A, Dufeu P, Kuhn S, et al. Psychopathological and behavioral correlates of dopaminergic sensitivity in alcohol-dependent patients. Arch Gen Psychiatry. 1996;53(12):1123–8.

    CAS  PubMed  Google Scholar 

  88. Knable MB, Jones DW, Coppola R, et al. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson’s disease. J Nucl Med. 1995;36(7):1216–25.

    CAS  PubMed  Google Scholar 

  89. Malhi GS, Parker GB, Greenwood J. Structural and functional models of depression: from sub-types to substrates. Acta Psychiatr Scand. 2005;111(2):94–105.

    CAS  PubMed  Google Scholar 

  90. Pizzagalli DA, Oakes TR, Fox AS, et al. Functional but not structural subgenual prefrontal cortex abnormalities in melancholia. Mol Psychiatry. 2004;9(4):325, 393–405.

    Google Scholar 

  91. Carey RJ. An examination of parkinsonian versus anhedonia contributions to self-stimulation impairments induced by dopamine dysfunction. Behav Brain Res. 1986;22(2):117–25.

    CAS  PubMed  Google Scholar 

  92. Wise RA, Spindler J, deWit H, et al. Neuroleptic-induced “anhedonia” in rats: pimozide blocks reward quality of food. Science. 1978;201(4352):262–4.

    CAS  PubMed  Google Scholar 

  93. Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl). 2004;171(2):121–32.

    CAS  Google Scholar 

  94. Scharfetter C. General psychopathology: an introduction. Cambridge: Cambridge University Press; 1980.

    Google Scholar 

  95. Delaville C, Chetrit J, Abdallah K, et al. Emerging dysfunctions consequent to combined monoaminergic depletions in Parkinsonism. Neurobiol Dis. 2012;45(2):763–73.

    CAS  PubMed  Google Scholar 

  96. Rampersaud N, Harkavyi A, Giordano G, et al. Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson’s disease with noradrenergic deficit. Br J Pharmacol. 2012;167(7):1467–79.

    CAS  PubMed  Google Scholar 

  97. Berridge KC, Kringelbach ML. Affective neuroscience of pleasure: reward in humans and animals. Psychopharmacology (Berl). 2008;199(3):457–80.

    CAS  Google Scholar 

  98. Faure A, Richard JM, Berridge KC. Desire and dread from the nucleus accumbens: cortical glutamate and subcortical GABA differentially generate motivation and hedonic impact in the rat. PLoS One. 2010;5(6):e11223.

    PubMed Central  PubMed  Google Scholar 

  99. Rolls ET, Kringelbach ML, de Araujo IE. Different representations of pleasant and unpleasant odours in the human brain. Eur J Neurosci. 2003;18(3):695–703.

    PubMed  Google Scholar 

  100. Keedwell PA, Andrew C, Williams SC, et al. The neural correlates of anhedonia in major depressive disorder. Biol Psychiatry. 2005;58(11):843–53.

    PubMed  Google Scholar 

  101. Salamone JD, Correa M, Mingote S, et al. Nucleus accumbens dopamine and the regulation of effort in food-seeking behavior: implications for studies of natural motivation, psychiatry, and drug abuse. J Pharmacol Exp Ther. 2003;305(1):1–8.

    CAS  PubMed  Google Scholar 

  102. Volkow ND, Wang GJ, Fischman MW, et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature. 1997;386(6627):827–30.

    CAS  PubMed  Google Scholar 

  103. Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol. 1998;80(1):1–27.

    CAS  PubMed  Google Scholar 

  104. Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev. 1998;28(3):309–69.

    CAS  PubMed  Google Scholar 

  105. Hazy TE, Frank MJ, O’Reilly RC. Neural mechanisms of acquired phasic dopamine responses in learning. Neurosci Biobehav Rev. 2010;34(5):701–20.

    CAS  PubMed Central  PubMed  Google Scholar 

  106. Reichmann H, Odin P, Brecht HM, et al. Changing dopamine agonist treatment in Parkinson’s disease: experiences with switching to pramipexole. J Neural Transm Suppl. 2006;71:17–25.

    CAS  PubMed  Google Scholar 

  107. Lemke MR. Depressive symptoms in Parkinson’s disease. Eur J Neurol. 2008;15 Suppl 1:21–5.

    PubMed  Google Scholar 

  108. Drijgers RL, Verhey FR, Tissingh G, et al. The role of the dopaminergic system in mood, motivation and cognition in Parkinson’s disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate. J Neurol Sci. 2012;320(1–2):121–6.

    CAS  PubMed  Google Scholar 

  109. Chaudhuri RK, Martinez-Martin P, Antonini A, et al. Rotigotine and specific non-motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013;19(7):660–5.

    Google Scholar 

  110. Maj M, Veltro F, Pirozzi R, et al. Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry. 1992;149(6):795–800.

    CAS  PubMed  Google Scholar 

  111. Willner P, Lappas S, Cheeta S, et al. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology (Berl). 1994;115(4):454–62.

    CAS  Google Scholar 

  112. Kondo T. Dopamine dysregulation syndrome. Hypothetical application of reward system stimulation for the treatment of anhedonia in Parkinson’s disease patients. J Neurol. 2008;255 Suppl 4:14–8.

    CAS  PubMed  Google Scholar 

  113. Giovannoni G, O’Sullivan JD, Turner K, et al. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68(4):423–8.

    CAS  PubMed  Google Scholar 

  114. Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90–9.

    PubMed Central  PubMed  Google Scholar 

  115. Picillo M, Rocco M, Barone P. Dopamine receptor agonists and depression in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15 Suppl 4:S81–4.

    PubMed  Google Scholar 

  116. Pizzagalli DA, Holmes AJ, Dillon DG, et al. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry. 2009;166(6):702–10.

    PubMed Central  PubMed  Google Scholar 

  117. Demyttenaere K, De Fruyt J, Stahl SM. The many faces of fatigue in major depressive disorder. Int J Neuropsychopharmacol. 2005;8(1):93–105.

    PubMed  Google Scholar 

  118. Schrijvers D, Hulstijn W, Sabbe BG. Psychomotor symptoms in depression: a diagnostic, pathophysiological and therapeutic tool. J Affect Disord. 2008;109(1–2):1–20.

    PubMed  Google Scholar 

  119. Stein DJ. Depression, anhedonia, and psychomotor symptoms: the role of dopaminergic neurocircuitry. CNS Spectr. 2008;13(7):561–5.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuropsychiatry Laboratory, I.R.C.C.S. Santa Lucia Foundation, Via Ardeatina, 306 – 00179, Rome, Italy

    Gianfranco Spalletta & Francesca Assogna

  2. Department of Neuroscience, University “Tor Vergata”, Rome, Italy

    Carlo Caltagirone

  3. Department of Clinical and Behavioral Neurology, I.R.C.C.S. Santa Lucia Foundation, Via Ardeatina, 306 – 00179, Rome, Italy

    Carlo Caltagirone

  4. Department of Psychiatry, Maastricht University Medical Centre, 5800, 6202AZ, Maastricht, The Netherlands

    Albert F. G. Leentjens

Authors
  1. Gianfranco Spalletta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Assogna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carlo Caltagirone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Albert F. G. Leentjens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gianfranco Spalletta .

Editor information

Editors and Affiliations

  1. Haifa & Sha'ar Menashe Mental Health Center, Israel Institute of Technology, Hadera, Israel

    Michael S. Ritsner

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Spalletta, G., Assogna, F., Caltagirone, C., Leentjens, A.F.G. (2014). Anhedonia in Parkinson’s Disease and Other Movement Disorders. In: Ritsner, M. (eds) Anhedonia: A Comprehensive Handbook Volume II. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-8610-2_13

Download citation

  • DOI: https://doi.org/10.1007/978-94-017-8610-2_13

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-017-8609-6

  • Online ISBN: 978-94-017-8610-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation